“This news brings great pride to France,” he said. “It shows we are pioneers in health care, that we can invent, that we can carry an innovation that will also bring great hope to plenty of people.”
Carmat won permission from the French authorities to test the human implants on four patients in three hospitals last September.
All were suffering from terminal heart failure.
While the intention is for each heart to keep a patient alive for five years, the success of the device in the trials will be judged on whether they survive with the implant for at least a month. Carmat hopes to finish human trials of the heart by the end of next year and to obtain approval to market the devices in the EU by early 2017.
It is expected to cost €140,000 (£120,000) to €180,000 (£150,000) if and when it goes on sale in Europe. The company’s shares have risen fivefold since floating on the Paris stock market in 2010. Among Carmat’s competitors in the race to perfect artificial heart implants are the privately-owned company, SynCardia Systems, and Abiomed, both of the United States.
The longest a patient has lived with a SynCardia heart is just under four years.
A spokesman for SynCardia said: “We’re very happy for them and we wish them the best in their pursuit.”
据英国《每日电讯报》12月21日报道,法国巴黎蓬皮杜医院医生成功地为病人体内植入一颗能为他延长寿命5年的人工心脏。
【法国成功为病患移植人工心脏】相关文章:
★ 英国央行任人唯才
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15